Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO(BMY) · Entity 1662 | Director | March 31, 2006 | April 04, 2006 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director | April 30, 2025 | May 03, 2025 |
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | Director | July 22, 2026 | July 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 31, 2006 · Filed April 04, 2006
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Share UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 22,932.28 |
Reported balance
After 2006-03-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2006-03-31 · Grant · Acquired 203.63 · Balance 22,932.28 F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Deferred share units are settled in cash either on a specified date in the future or following the cessation of the reporting person's service as a director.
Emergent BioSolutions Inc.
Report date April 30, 2025 · Filed May 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 139,098 |
Reported balance
After 2025-04-30 transaction · row 1
1 source rowRow 1 · 2025-04-30 · Grant · Acquired 34,403 · Balance 139,098 F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.45 · Expires 2032-04-29 | Direct | 41,572 |
Reported balance
After 2025-04-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-04-30 · Grant · Acquired 15,824 · Balance 41,572 F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price. F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual grant of restricted stock units ("RSUs") granted under the Company's Stock Incentive plan, as amended and restated, for Board and Committee service. Each RSU represents a right to receive one share of Emergent BioSolutions Inc. (the "Company") common stock upon vesting. The shares underlying the RSUs will vest on the day prior to the one-year anniversary of the grant date ("Annual Grant Vesting Date"), subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date.
F2: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated, for Board and Committee service. The shares underlying the options will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors through the Annual Grant Vesting Date. Each stock option represents a right to purchase one share of the Company's common stock upon vesting at the exercise price.
F3: The number of options granted was determined by multiplying 25% of the total non-employee director compensation value, and then dividing by the Black-Scholes value of a single option calculated as of the date of the grant.
UNITED THERAPEUTICS Corp
Report date July 22, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $527.07 · Expires 2033-07-22 | Direct | 2,380 |
Reported balance
After 2026-07-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-22 · Grant · Acquired 2,380 · Balance 2,380 F3: Annual non-employee director award. F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders. |
| Common StockSEC Table I · non-derivative | Direct | 2,983 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,983 F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026. |
| Common StockSEC Table I · non-derivative | Indirectby Trust | 1,457 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,457 F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power. |
Filing footnotes · ownership attribution and instrument terms
F1: Total has been updated to correct a clerical error which caused the reporting person's indirect holding of common stock (by trust) to be underreported by 590 shares in the Form 4 filed on July 13, 2026 by the reporting person. These shares are in addition to the 2,903 shares held directly, as reported in the Form 4 filed on July 13, 2026.
F2: These securities are held indirectly by a trust over which the reporting person has sole investment power and sole voting power.
F3: Annual non-employee director award.
F4: Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2021 Filed May 11, 2021 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,118 | $61.62 | $192,131.16 |
DisclosureSEC source: 0001367644-21-000075 · wf-form4_162076428587593.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,945 F1 · security: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting persons exercise price for the reported stock option exercise. Read SEC document |
| May 10, 2021 Filed May 11, 2021 20:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 10,305 | $18.64 | $192,085.20 |
DisclosureSEC source: 0001367644-21-000075 · wf-form4_162076428587593.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 20:24 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GiftCommon Stock | 10,004 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000147 · wf-form4_160046066724906.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,758 F1 · security: This transaction represents a gift / charitable donation to the Sullivan Family Foundation. This is not a market transaction, thus no price has been reported. No value was received for the gifted shares. Read SEC document |
| September 02, 2020 Filed Sep 5, 2020 00:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $20.08 | $0.00 |
DisclosureSEC source: 0001367644-20-000145 · wf-form4_159926448444099.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,786 Underlying: Common Stock · 7,893 shares Expires 2021-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F5 · derivative.exercise_date: The option grant is fully vested. Read SEC document |
| September 02, 2020 Filed Sep 5, 2020 00:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $111.23 | $877,903.66 |
DisclosureSEC source: 0001367644-20-000145 · wf-form4_159926448444099.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,762 F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices between $110.96 and $111.32. Read SEC document |
| September 02, 2020 Filed Sep 5, 2020 00:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $20.08 | $158,491.44 |
DisclosureSEC source: 0001367644-20-000145 · wf-form4_159926448444099.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. Read SEC document |
| September 02, 2020 Filed Sep 5, 2020 00:08 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 20,525 | $111.22 | $2,282,702.24 |
DisclosureSEC source: 0001367644-20-000145 · wf-form4_159926448444099.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,762 F1 · security: Consists of previously exercised options granted under the company's stock incentive plan as amended and restated. F2 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices between $110.96 and $111.40. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 18:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 5,160 | $0.00 Strike: $119.76 | $0.00 |
DisclosureSEC source: 0001104659-20-078807 · a4.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,160 Underlying: Common Stock · 5,160 shares Expires not disclosed F6 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F7 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. F8 · derivative.expiration_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 18:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 1,680 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078807 · a4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,680 Underlying: Common Stock · 1,680 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F5 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 18:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | Not disclosed | $0.00 Strike: $0.00 | $2,300.00 |
DisclosureSEC source: 0001104659-20-078807 · a4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 18:03 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-078807 · a4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares received upon vesting of restricted stock units on June 26, 2020. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 21, 2020 Filed May 26, 2020 13:14 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 2,821 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000079 · wf-form4_159049886892375.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,287 F1 · security: Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 15,000 | $0.00 Strike: $48.11 | $0.00 |
DisclosureSEC source: 0001127602-20-012082 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Share tracking awards are non-dilutive cash-settled stock appreciation rights, which may only be settled in cash and may not be converted into shares of common stock. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 15,000 | $90.54 | $1,358,100.00 |
DisclosureSEC source: 0001127602-20-012082 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,120 Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 20:33 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 15,000 | $48.11 | $721,650.00 |
DisclosureSEC source: 0001127602-20-012082 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 6,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-20-011861 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 6,000 | $83.95 | $503,700.00 |
DisclosureSEC source: 0001127602-20-011861 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,120 Read SEC document |
| March 23, 2020 Filed Mar 24, 2020 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 6,000 | $54.77 | $328,620.00 |
DisclosureSEC source: 0001127602-20-011861 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 7,893 | $13.00 Strike: $13.00 | $102,609.00 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · derivative · entry 6 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2020-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionEmployee Stock Options (Right to Buy) · Derivative | 7,893 | $14.71 Strike: $14.71 | $116,106.03 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · derivative · entry 5 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2020-05-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of stock options granted under the Company's Stock Incentive Plan, as amended and restated. F3 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $58.96 | $465,357.07 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · nonDerivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,466 F1 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices at prices ranging from $58.75 to $59.14. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $14.71 | $116,106.03 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · nonDerivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 7,893 | $58.96 | $465,357.07 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,466 F1 · price: The price reported is a weighted average sale price. These shares were sold in multiple transactions at prices at prices ranging from $58.75 to $59.14. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 21:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $13.00 | $102,609.00 |
DisclosureSEC source: 0001367644-20-000025 · wf-form4_158353064805074.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-023014 · form4.xml · derivative · entry 4 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F7 · derivative.exercise_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. F7 · derivative.expiration_date: The restricted stock units vest on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Shares will be issued to the reporting person upon vesting unless the reporting person has elected to defer receipt of shares. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantStock Options · Derivative | 6,310 | $0.00 Strike: $76.36 | $0.00 |
DisclosureSEC source: 0001127602-19-023014 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,310 Underlying: Common Stock · 6,310 shares Expires 2029-06-26 F5 · shares: Annual non-employee director grant of stock options, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F6 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | GrantRestricted Stock Units · Derivative | 2,300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-023014 · form4.xml · derivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Underlying: Common Stock · 2,300 shares Expires 2029-06-26 F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock. F3 · shares: Annual non-employee director grant of restricted stock units, which are awarded and priced each year on the date of the issuer's Annual Meeting of Shareholders. F4 · derivative.exercise_date: Award becomes fully vested on the one-year anniversary of the grant date only if the reporting person attends at least 75% of the regularly scheduled meetings of the issuer's Board and his or her committee meetings from the date of grant until the date of the issuer's next annual meeting of shareholders. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 20:13 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-023014 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares received upon vesting of restricted stock units on June 26, 2019. Restricted stock units converted on a one-for-one basis into shares of common stock. Read SEC document |
| May 23, 2019 Filed May 29, 2019 00:12 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012276 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,466 F1 · security: Consists of restricted stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the earlier of: (i) the day prior to the first anniversary of the date of grant, or (ii) the day prior to annual shareholder meeting; assuming continued service with the company. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,893 | $0.00 Strike: $13.37 | $0.00 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,893 shares Expires 2019-05-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of options granted under the company's stock incentive plan, as amended and restated. F3 · derivative.exercise_date: The option vested in three equal installments in May 2013, May 2014 and May 2015. Each option represents the right of the reporting person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided by the grant agreement. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,135 | $49.41 | $105,490.35 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,730 F1 · shares: Consists of shares owned by the reporting person and delivered to the issuer to satisfy the reporting person's exercise price for the reported stock option exercise. Read SEC document |
| May 07, 2019 Filed May 9, 2019 21:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 7,893 | $13.37 | $105,529.41 |
DisclosureSEC source: 0001567619-19-010316 · doc1.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,865 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:25 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-19-009627 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:25 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $126.84 | $126,840.00 |
DisclosureSEC source: 0001127602-19-009627 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:25 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-19-009627 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 23:12 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-19-003854 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 23:12 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $115.83 | $115,830.00 |
DisclosureSEC source: 0001127602-19-003854 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 23:12 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-19-003854 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-19-000648 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $107.65 | $107,650.00 |
DisclosureSEC source: 0001127602-19-000648 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:02 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-19-000648 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-035077 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $119.53 | $119,530.00 |
DisclosureSEC source: 0001127602-18-035077 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| December 03, 2018 Filed Dec 4, 2018 21:04 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-035077 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-18-031860 · form4.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $115.04 | $115,040.00 |
DisclosureSEC source: 0001127602-18-031860 · form4.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,370 F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 20:10 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-18-031860 · form4.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise of share tracking awards was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person. Read SEC document |
| November 01, 2018 Filed Jan 21, 2020 21:02 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionShare Tracking Award · Derivative | 1,000 | $0.00 Strike: $54.77 | $0.00 |
DisclosureSEC source: 0001127602-20-002078 · form4a.xml · derivative · entry 3 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 1,000 shares Expires 2021-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Transaction was inadvertently entered as an "A" for "Acquired". The correct code for this transaction is "D" for "Disposed". This error caused an overstated balance of this tranche of Share Tracking Awards (by 1,000 awards), which is correct by this amendment. Read SEC document |
| November 01, 2018 Filed Jan 21, 2020 21:02 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Disposition to issuerCommon Stock | 1,000 | $115.04 | $115,040.00 |
DisclosureSEC source: 0001127602-20-002078 · form4a.xml · nonDerivative · entry 2 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,370 Read SEC document |
| November 01, 2018 Filed Jan 21, 2020 21:02 UTC Amendment | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 1,000 | $54.77 | $54,770.00 |
DisclosureSEC source: 0001127602-20-002078 · form4a.xml · nonDerivative · entry 1 SULLIVAN LOUIS W · CIK 0001193522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was inadvertently entered as a "D" for Disposed. The correct code for this transaction is "A" for Acquired. This error caused an understated balance of common stock (by 2,000) which is corrected by this amendment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.